职务：

广州医科大学副校长

职称：

教授

研究方向：

间质性肺病和肺血管病

研究工作：

长期致力于性别差异背景下心肺血管疾病的调控效应及机制研究。目前的研究方向为：

1、雌激素通过m6A表观遗传修饰影响肺动脉高压发生发展的机制。

2、雌激素调控泛素化修饰在肺动脉高压中发生发展中的作用。

3、雌激素调控淋巴管新生在肺动脉高压发生中的作用。

科研项目：

1、2021年国家自然科学基金面上项目，常氧/低氧状态下雌激素逆向调控肺动脉血管平滑肌细胞METTL3/PFKFB3表达及肺动脉高压发生的作用机制研究。资助经费：54万。主持，在研。

2、2018年国家自然科学基金面上项目，FSH调控miR-7641/Twist1诱导内皮间充质转化及动脉粥样斑块不稳定性。资助经费：57万。主持，已结题。

3、2014年国家自然科学基金面上项目，雌激素促内皮硫化氢释放的非基因效应及其机制研究。资助经费：70万。主持，已结题。

4. 2011年国家自然科学基金面上项目，FSH促进绝经后动脉粥样硬化形成的效应及其机制研究。资助经费：70万。主持，已结题。

5、2010年国家自然科学基金青年项目，内皮源性硫化氢在雌激素延缓动脉粥样斑块形成中的作用及其机制研究。资助经费：22万。主持，已结题。

代表性学术论文：

1、1.Xiaosa Li#, Ping Li#, Yuqin Chen#, Jiale Wang, Hao Wen, Xingyan Xu, Jian Wang, Yiming Xu, Tommaso Simoncini*, Wenju Lu*, Dongxing Zhu*, Xiaodong Fu*†. Estrogen oppositely regulates pulmonary hypertension via METTL3/PFKFB3 under normoxia and hypoxia. Hypertension, In revision. IF:8.3

2、Zhao X, Li X, Liu P, Li P, Xu X, Chen Y, Cheng Y*, Zhu D*, Fu X*. 17β-estradiol promotes angiogenesis through non-genomic activation of Smad1 signaling in endometriosis. Vascul Pharmacol. 2022 Feb;142:106932. IF:4.0

3、Xu X, Yan Q, Liu X, Li P, Li X, Chen Y, Simoncini T, Liu J*, Zhu D*, Fu X*. 17β-Estradiol nongenomically induces vascular endothelial H2S release by promoting phosphorylation of cystathionine γ-lyase. J Biol Chem. 2019 Oct 25;294(43):15577-15592. IF:4.8

4、Teoh JP, Li X, Simoncini T, Zhu D*, Fu X*. Estrogen-Mediated Gaseous Signaling Molecules in Cardiovascular Disease. Trends Endocrinol Metab. 2020 Oct;31(10):773-784. IF:10.9

5、Zhu D, Li X, Macrae VE*, Simoncini T*, Fu X*. Extragonadal Effects of Follicle-Stimulating Hormone on Osteoporosis and Cardiovascular Disease in Women during Menopausal Transition. Trends Endocrinol Metab. 2018 Aug;29(8):571-580. IF:10.9

6、Zhao L, Cao X, Li L, Wang X, Wang Q, Jiang S, Tang C, Zhou S, Xu N, Cui Y, Hu W, Fei L, Zheng Z, Chen L, Schmidt MO, Wei Q, Zhao J, Labes R, Patzak A, Wilcox CS, Fu X*, Wellstein A*, Lai EY*. Acute Kidney Injury Sensitizes the Brain Vasculature to Ang II (Angiotensin II) Constriction via FGFBP1 (Fibroblast Growth Factor Binding Protein 1). Hypertension. 2020 Dec;76(6):1924-1934. IF:8.3

7、Cao K, Zhang T, Li Z, Song M, Li A, Yan J, Guo S, Wang L, Huang S, Li Z, Hou W, Dai X, Wang Y, Feng D, He J, Fu X*, Xu Y*. Glycolysis and de novo fatty acid synthesis cooperatively regulate pathological vascular smooth muscle cell phenotypic switching and neointimal hyperplasia. J Pathol. 2023 Apr;259(4):388-401.IF:7.3

8、Chen Z, Gordillo-Martinez F, Jiang L, He P, Hong W, Wei X, Staines KA, Macrae VE, Zhang C, Yu D*, Fu X*, Zhu D*. Zinc ameliorates human aortic valve calcification through GPR39 mediated ERK1/2 signalling pathway. Cardiovasc Res. 2021 Feb 22;117(3):820-835. IF:10.9

9、Wang S, Yu H, Gao J, Chen J, He P, Zhong H, Tan X, Staines KA, Macrae VE, Fu X*, Jiang L*, Zhu D*. PALMD regulates aortic valve calcification via altered glycolysis and NF-κB-mediated inflammation. J Biol Chem. 2022 May;298(5):101887. IF:4.8

10、Zhong H, Yu H, Chen J, Mok SWF, Tan X, Zhao B, He S, Lan L, Fu X*, Chen G*, Zhu D*. The short-chain fatty acid butyrate accelerates vascular calcification via regulation of histone deacetylases and NF-κB signaling. Vascul Pharmacol. 2022 Oct;146:107096. IF:4.0

11、He P, Yu H, Jiang L, Chen Z, Wang S, Macrae VE, Fu X*, Zhu D*. Hdac9 inhibits medial artery calcification through down-regulation of Osterix. Vascul Pharmacol. 2020 Sep;132:106775. IF:4.0

联系方式：

Email: fuxiaod@gzhmu.edu.cn